Bristol-Myers To Market Two Cancer Drugs in Japan Next Year
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb says it plans to begin marketing a pair of cancer drugs in Japan next year. The U.S. company applied for market approval from Japan's Ministry of Health, Labor and Welfare for the two drugs and expects to begin marketing the first, Sprycel (sasatinib) for chronic myeloid leukemia early in 2009. Next, Bristol is looking to sell its Ixempra (ixabepilone) for treating breast cancer as early as the second half of 2009 or the first half of 2010. CEO Lamberto Andreotti says that with both drugs on the market, Bristol hopes to double its annual revenues in Japan over the next five years. (Click here for more - a subscription may be required